Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole
Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole
复制标题
DOI：
10.1158/0008-5472.can-05-0067
复制
发表时间：
2005-04-15
期刊：
影响因子：
11.2
通讯作者：
Maihle, NJ
中科院分区：
文献类型：
--
作者：
Lafky, JM;Baron, LT;Maihle, NJ
以前的研究表明雌激素是乳腺肿瘤中表皮生长因子受体（EGFR）表达的调节因子。因此，我们推测，雌激素可能会调节血清可溶性EGFR（sEGFR）的浓度在乳腺癌患者。因此，我们测量了用来曲唑（一种阻断雌激素合成的芳香酶抑制剂）治疗的绝经后转移性乳腺癌（MBC）妇女的血清sEGFR浓度。在来曲唑治疗前和治疗后1个月和3个月采集血清标本。我们报道来曲唑治疗前MBC患者与年龄和绝经后匹配的健康女性之间sEGFR浓度无差异（P = 0.468）。然而，与治疗前浓度相比，来曲唑治疗1个月（P = 0.006）和3个月（P = 0.003）后，76%的MBC患者的sEGFR浓度显著降低。在本研究的限制范围内，我们没有发现治疗前sEGFR浓度或治疗后sEGFR浓度降低与无进展生存期或总生存期之间存在关联的证据。尽管如此，我们的结论是，未来的前瞻性研究是必要的，以确定是否基线和/或纵向血清sEGFR浓度可能是有用的预测疾病进展和生存，和/或监测芳香化酶抑制剂或其他内分泌治疗乳腺癌患者的反应。
Previous studies have implicated estrogen as a regulator of epidermal growth factor receptor (EGFR) expression in breast tumors. We therefore speculated that estrogen might modulate serologic soluble EGFR (sEGFR) concentrations in breast cancer patients. Accordingly, we measured serum sEGFR concentrations in postmenopausal women with metastatic breast cancer (MBC) treated with letrozole, an aromatase inhibitor that blocks estrogen synthesis. Serum specimens were obtained prior to and following 1 and 3 months of letrozole therapy. We report that sEGFR concentrations do not differ between MBC patients prior to letrozole treatment and age-and postmenopause-matched healthy women (P = 0.468). In contrast, however, sEGFR concentrations decreased significantly in 76% of MBC patients after both 1 month (P = 0.006) and 3 months (P = 0.003) of letrozole therapy versus pretreatment concentrations. Within the limitations of this study, we found no evidence for an association between pretreatment sEGFR concentrations or decreased treatment sEGFR concentrations and either progression-free or overall survival. Nonetheless, we conclude that future prospective studies are warranted to determine if baseline and/or longitudinal serum sEGFR concentrations may be useful for predicting disease progression and survival, and/or for monitoring responsiveness to aromatase inhibitors or other endocrine therapies in breast cancer patients.